Table 2.
Pathologic and perioperative outcomes.
| Variables | Total (n = 50) | Phase I (n = 24) | Phase II (n = 26) | p-value |
|---|---|---|---|---|
| Postoperative Scrc (µmol/L), mean (SD) | 76.81 (23.03) | 80.52 (28.15) | 73.40 (16.88) | 0.22 |
| Scr changec (µmol/L), mean (SD) | 3.30 (7.38) | 4.28 (5.75) | 2.40 (8.64) | 0.44 |
| Postoperative eGFRc (ml/min), mean (SD) | 94.33 (20.56) | 92.17 (19.79) | 96.33 (21.44) | 0.39 |
| eGFR changec (%), mean (SD) | −2.88 (6.69) | −3.38 (5.75) | −2.42 (7.55) | 0.76 |
| Postoperative Hba (g/L), mean (SD) | 127.68 (20.56) | 128.21 (18.85) | 127.19 (22.38) | 0.86 |
| Hb changec (g/L), mean (SD) | −15.26 (14.62) | −13.37 (11.01) | −17 (17.35) | 0.44 |
| EBLc (ml), mean (SD) | 119.2 (185.18) | 117.92 (164.74) | 120.38 (205.53) | 0.78 |
| PLOSc (d), mean (SD) | 4.8 (1.22) | 5.33 (1.46) | 4.30 (0.68) | 0.04 |
| OTa (min), mean (SD) | 124.04 (31.55) | 133.5 (35.56) | 115.31 (24.95) | 0.04 |
| Console timec (min), mean (SD) | 91.8 (32.1) | 103.21 (33.76) | 81.27 (27.04) | 0.01 |
| Trifecta achievementc, n (%) | 43 (86) | 22 (91.7) | 21 (80.8) | 0.27 |
| Clavien-Dindo grade complicationsb, n (%) | 0.60 | |||
| <2 | 50 (94.3) | 23 (95.8) | 27 (93.1) | |
| ≥2 | 3 (5.7) | 1 (4.2) | 2 (6.9) | |
| Positive Surgical Marginsb, n (%) | 0 | 0 | 0 | 1.00 |
| Histologyb, n (%) | 0.41 | |||
| Benign | 12 (24) | 7 (29.2) | 5 (19.2) | |
| Malignant | 38 (76) | 17 (70.8) | 21 (80.8) |
EBL, estimated blood loss; PLOS, postoperative length of hospital stay; OT, operative time; SD, standard deviations.
a
t-test.
b
χ2–test.
c
U-test.